| 1 |
31810002 | Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma. | 2020 Jan |
5 |
| 2 |
31821983 | Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer. | 2020 Jan |
2 |
| 3 |
31833081 | Quantitative Proteomics Analysis Reveals Nuclear Perturbation in Human Glioma U87 Cells treated with Temozolomide. | 2020 Mar |
3 |
| 4 |
31863352 | Survey of treatment recommendations for elderly patients with glioblastoma. | 2020 Aug |
1 |
| 5 |
31865606 | IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. | 2020 Aug |
3 |
| 6 |
31916238 | A Key Role of DNA Damage-Inducible Transcript 4 (DDIT4) Connects Autophagy and GLUT3-Mediated Stemness To Desensitize Temozolomide Efficacy in Glioblastomas. | 2020 Jul |
2 |
| 7 |
31964274 | Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition. | 2020 Jan |
4 |
| 8 |
32020475 | First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. | 2020 Feb |
6 |
| 9 |
32032585 | Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. | 2020 May |
1 |
| 10 |
32070670 | Immunohistochemistry for O6-methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients' progression-free survival with the cut-off value determined by ROC analysis. | 2020 Mar |
2 |
| 11 |
32075134 | A "Clickable" Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT. | 2020 Feb 14 |
3 |
| 12 |
31571099 | MGMT immunohistochemistry in pituitary tumors: controversies with clinical implications. | 2019 Dec |
4 |
| 13 |
31611911 | A Novel DNA Methylation-Based Signature Can Predict the Responses of MGMT Promoter Unmethylated Glioblastomas to Temozolomide. | 2019 |
9 |
| 14 |
31680769 | FoxD2-AS1 is a prognostic factor in glioma and promotes temozolomide resistance in a O6-methylguanine-DNA methyltransferase-dependent manner. | 2019 Nov |
2 |
| 15 |
31717973 | Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Comment on Strobel et al., Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines 2019, 7, 69. | 2019 Nov 11 |
3 |
| 16 |
31721137 | Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities. | 2019 Dec |
1 |
| 17 |
31725331 | SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT. | 2019 Dec |
5 |
| 18 |
31783653 | On the Critical Issues in Temozolomide Research in Glioblastoma: Clinically Relevant Concentrations and MGMT-independent Resistance. | 2019 Nov 27 |
4 |
| 19 |
31798765 | HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1. | 2019 |
11 |
| 20 |
31810938 | Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair. | 2019 Dec |
1 |
| 21 |
31814867 | Polyphyllin VII Promotes Apoptosis and Autophagic Cell Death via ROS-Inhibited AKT Activity, and Sensitizes Glioma Cells to Temozolomide. | 2019 |
1 |
| 22 |
32039031 | MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. | 2019 |
2 |